IOVA Iovance Biotherapeutics
WatchlistIovance Biotherapeutics News
The healthcare racetrack never gets old! Goldman Sachs pushes these two “potentially big bull stocks” in the US stock market
For investors seeking stable returns, few stocks can provide a better combination of risk, return, and opportunity than healthcare stocks.
Crude Oil Gains Over 2%; PaxMedica Shares Plunge
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 100 points on Monday. The Dow traded up 0.34% to 35,064.42 while the NASDAQ rose 0.80% to 14,238.67. The S&P 500
Why Iovance Biotherapeutics Stock Is Jumping Today
IOVA, YPF and SMR Are Among Pre Market Gainers
Goldman Sachs Initiates Coverage On Iovance Biotherapeutics With Buy Rating, Announces Price Target of $12
Goldman Sachs analyst Andrea Tan initiates coverage on Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy rating and announces Price Target of $12.
Iovance Biotherapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/20/2023 134.37% Goldman Sachs → $12 Initiates Coverage On → Buy 11/08/2023 446.87% HC Wainwright & Co.
Buy Rating on Iovance Biotherapeutics: Promising Future With TIL Therapies and Blockbuster Opportunity
Iovance Biotherapeutics: A Promising Investment With Upcoming Commercial Approval and Solid Tumor Trials Advancements
Mizuho Securities Recommends 'Buy' for Iovance Biotherapeutics: Strategic Prioritization, Upcoming FDA Meeting, and Strong Commercial Opportunity Highlighted
Positive Outlook for Iovance Biotherapeutics: Promising Regulatory Progress and Increased Revenue Opportunities
5 OTC Stocks With The Potential To Explode In 2024
Despite the risk, investing in over-the-counter (OTC) stocks remains popular for one reason: the potential for a massive return on investment. While there's no way of knowing what 2024 will hold — esp
Analyst Expectations for Iovance Biotherapeutics's Future
Analysts have provided the following ratings for Iovance Biotherapeutics (NASDAQ:IOVA) within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings73000Last 30D10000
HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $28
HC Wainwright & Co. analyst Joseph Pantginis maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $38 to $28.
Promising Future Projections and Robust Financial Health Drive Buy Rating for Iovance Biotherapeutics
Recap: Iovance Biotherapeutics Q3 Earnings
Iovance Biotherapeutics (NASDAQ:IOVA) reported its Q3 earnings results on Tuesday, November 7, 2023 at 04:01 PM.Here's what investors need to know about the announcement.EarningsIovance Biotherapeutic
Earnings Flash (IOVA) IOVANCE BIOTHERAPEUTICS Posts Q3 Revenue $469,000, Vs. Street Est of $4.9M
04:04 PM EST, 11/07/2023 (MT Newswires) -- Earnings Flash (IOVA) IOVANCE BIOTHERAPEUTICS Posts Q3 Revenue $469,000, vs. Street Est of $4.9M
Iovance Biotherapeutics Q3 2023 EPS $(0.46) Misses $(0.45) Estimate, Sales $469.00K Miss $4.19M Estimate
Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.45) by 2.22 percent. This is a 26.98 percent increase over losse
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act Action (PDUFA) Date of February 24, 2023Positive Regulatory
Earnings Preview: Iovance Biotherapeutics
Iovance Biotherapeutics (NASDAQ:IOVA) is set to give its latest quarterly earnings report on Tuesday, 2023-11-07. Here's what investors need to know before the announcement.Analysts estimate that Iova
Promising Outlook for Iovance Biotherapeutics With Lifileucel Approval and Strong Cash Position: Reni Benjamin's Analysis